E. Winton

1.4k total citations
23 papers, 608 citations indexed

About

E. Winton is a scholar working on Hematology, Genetics and Oncology. According to data from OpenAlex, E. Winton has authored 23 papers receiving a total of 608 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Hematology, 7 papers in Genetics and 6 papers in Oncology. Recurrent topics in E. Winton's work include Acute Myeloid Leukemia Research (6 papers), Hematopoietic Stem Cell Transplantation (4 papers) and Chronic Lymphocytic Leukemia Research (3 papers). E. Winton is often cited by papers focused on Acute Myeloid Leukemia Research (6 papers), Hematopoietic Stem Cell Transplantation (4 papers) and Chronic Lymphocytic Leukemia Research (3 papers). E. Winton collaborates with scholars based in United States and Canada. E. Winton's co-authors include H. Kent Holland, C D Hillyer, John R. Wingard, Leonard T. Heffner, S P Dix, S M Devine, Robert B. Geller, Rein Saral, Richard E. Mullins and C. Gilmore and has published in prestigious journals such as Journal of Clinical Oncology, Blood and FEBS Letters.

In The Last Decade

E. Winton

23 papers receiving 598 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
E. Winton United States 13 403 148 134 112 88 23 608
Ted Gooley United States 9 419 1.0× 123 0.8× 94 0.7× 53 0.5× 63 0.7× 15 614
Jennifer Treleaven United Kingdom 14 474 1.2× 269 1.8× 86 0.6× 206 1.8× 74 0.8× 30 743
P Hentschke Sweden 15 604 1.5× 255 1.7× 109 0.8× 59 0.5× 62 0.7× 25 791
Nicole A. Carreau United States 9 410 1.0× 159 1.1× 66 0.5× 157 1.4× 150 1.7× 12 677
S Kulkarni United Kingdom 18 692 1.7× 334 2.3× 93 0.7× 256 2.3× 104 1.2× 32 810
EC Guinan United States 9 365 0.9× 200 1.4× 97 0.7× 92 0.8× 63 0.7× 14 734
Ch. Salmon France 14 355 0.9× 70 0.5× 32 0.2× 132 1.2× 85 1.0× 59 589
Marion Sternbach Canada 10 263 0.7× 126 0.9× 27 0.2× 126 1.1× 98 1.1× 17 529
Annika Elmhorn‐Rosenborg Sweden 7 144 0.4× 150 1.0× 72 0.5× 141 1.3× 186 2.1× 9 454
Giuseppina Mele Italy 16 549 1.4× 149 1.0× 215 1.6× 132 1.2× 147 1.7× 41 698

Countries citing papers authored by E. Winton

Since Specialization
Citations

This map shows the geographic impact of E. Winton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E. Winton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E. Winton more than expected).

Fields of papers citing papers by E. Winton

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E. Winton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E. Winton. The network helps show where E. Winton may publish in the future.

Co-authorship network of co-authors of E. Winton

This figure shows the co-authorship network connecting the top 25 collaborators of E. Winton. A scholar is included among the top collaborators of E. Winton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E. Winton. E. Winton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Radia, Deepti, Jason Gotlib, Mark W. Drummond, et al.. (2019). S830 AVAPRITINIB, A POTENT AND SELECTIVE INHIBITOR OF KIT D816V, INDUCES COMPLETE AND DURABLE RESPONSES IN PATIENTS (PTS) WITH ADVANCED SYSTEMIC MASTOCYTOSIS (ADVSM). HemaSphere. 3(S1). 368–368. 7 indexed citations
2.
Winton, E., Edmund K. Waller, Leonard T. Heffner, et al.. (2008). Long-term progression-free survival after early autologous transplantation for mantle-cell lymphoma. Bone Marrow Transplantation. 42(8). 529–534. 13 indexed citations
3.
Langston, Amelia, Sagar Lonial, Kenneth J. Smith, et al.. (2004). A Phase I Trial of Ara-C, Topotecan, and Gemtuzumab Ozogamicin (Mylotarg®) for Advanced MDS and Secondary or Relapsed AML.. Blood. 104(11). 1814–1814. 1 indexed citations
4.
Devine, Steve, RB Geller, Liming Lin, et al.. (1997). The outcome of unrelated donor bone marrow transplantation in patients with hematologic malignancies using tacrolimus (FK506) and low dose methotrexate for graft-versus-host disease prophylaxis.. PubMed. 3(1). 25–33. 31 indexed citations
5.
Winton, E., et al.. (1996). Reverse Transcriptase-Polymerase Chain Reaction forbcr/ablFusion in Chronic Myelogenous Leukemia. American Journal of Clinical Pathology. 105(6). 756–760. 9 indexed citations
6.
7.
Dix, S P, John R. Wingard, Richard E. Mullins, et al.. (1996). Association of busulfan area under the curve with veno-occlusive disease following BMT.. PubMed. 17(2). 225–30. 262 indexed citations
8.
Hillyer, Christopher D., Alexander Duncan, Timothy J. Barrett, et al.. (1995). Chemotherapy‐induced hemolytic uremic syndrome: Description of a potential animal model. Journal of Medical Primatology. 24(2). 68–73. 10 indexed citations
9.
Larson, Richard A., Roger Day, N. Azarnia, et al.. (1992). The selective use of AMSA following high‐dose cytarabine in patients with acute myeloid leukaemia in relapse: a Leukemia Intergroup Study. British Journal of Haematology. 82(2). 337–346. 13 indexed citations
10.
Vogler, William R., David P. Harrington, E. Winton, et al.. (1992). Phase II clinical trial of carboplatin in relapsed and refractory leukemia.. PubMed. 6(10). 1072–5. 18 indexed citations
11.
Winton, E., Martha C. Monroe, Robert C. Holman, et al.. (1991). Recombinant human granulocyte-macrophage colony-stimulating factor promotes megakaryocyte maturation in nonhuman primates.. PubMed. 19(8). 810–6. 22 indexed citations
12.
Vogler, William R., et al.. (1990). Therapy of acute myelogenous leukemia in patients over the age of 50: A randomized southeastern cancer study group trial. Leukemia Research. 14(10). 895–903. 23 indexed citations
13.
14.
Elfenbein, Gerald J., Jeffrey P. Krischer, Robert Hong, et al.. (1989). Interim results of a multicenter trial to prevent cytomegalovirus pneumonia after allogeneic bone marrow transplantation.. PubMed. 21(1 Pt 3). 3099–100. 7 indexed citations
15.
Elfenbein, Gerald J., Jeffrey P. Krischer, Kenneth H. Rand, et al.. (1987). Preliminary results of a multicenter trial to prevent death from cytomegalovirus pneumonia with intravenous immunoglobulin after allogeneic bone marrow transplantation.. PubMed. 19(6 Suppl 7). 138–43. 13 indexed citations
16.
Winton, E., et al.. (1987). Use of long-term human marrow cultures to demonstrate progenitor cell precursors in marrow treated with 4-hydroperoxycyclophosphamide.. PubMed. 15(6). 710–4. 40 indexed citations
17.
McDougal, J. Steven, Melanie S. Kennedy, Marjorie Hubbard, et al.. (1986). Antigen detection in immune complexes by a modified Staphylococci binding assay and Western blot analysis. Clinical Immunology and Immunopathology. 38(2). 184–197. 4 indexed citations
18.
Goldberg, Jack, Hans Grünwald, William R. Vogler, et al.. (1985). Treatment of patients with acute nonlymphocytic leukemia in relapse: A leukemia intergroup study. American Journal of Hematology. 19(2). 167–176. 7 indexed citations
19.
Winton, E., et al.. (1981). Intensive chemotherapy with daunorubicin, 5-azacytidine, 6-thioguanine, and cytarabine (DATA) for the blastic transformation of chronic granulocytic leukemia.. PubMed. 65(5-6). 389–92. 16 indexed citations
20.
Hubbard, Mark, et al.. (1975). Hemoglobin atlanta or α2β275 Leu→Pro (E19); An unstable variant found in several members of a caucasian family. Biochimica et Biophysica Acta (BBA) - Protein Structure. 386(2). 538–541. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ted Gooley Breakdown of academic impact, for papers by Jennifer Treleaven Breakdown of academic impact, for papers by P Hentschke Breakdown of academic impact, for papers by Nicole A. Carreau Breakdown of academic impact, for papers by S Kulkarni Breakdown of academic impact, for papers by EC Guinan Breakdown of academic impact, for papers by Ch. Salmon Breakdown of academic impact, for papers by Marion Sternbach Breakdown of academic impact, for papers by Annika Elmhorn‐Rosenborg Breakdown of academic impact, for papers by Giuseppina Mele
Rankless by CCL
2026